A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GLP-1 / glucagon-like peptide-1 receptor

[Related PubMed/MEDLINE]
Total Number of Papers: 15
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   GLP-1  (>> Co-occurring Abbreviation)
Long Form:   glucagon-like peptide-1 receptor
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Analysis of patient-specific factors contributing to effectiveness of glucagon-like peptide-1 receptor agonists. HbA1c
2020 Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases. DPP-4, eGFR, ESKD, SGLT2i
2020 Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. FXR, IR, NAFLD
2019 Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. DPP-4, FAO, FXR, IR, NAFLD, NASH, SGLT2
2019 Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom. HCP, T2D, UK, USA
2019 Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. DPP-4, HRs, IR, SGLT2, UTIs
2017 Geographical variation in anti-diabetic prescribing in Ireland in 2013 and 2014: a cross-sectional analysis. DPP-4, SCV
2016 Mechanisms of improved glucose handling after metabolic surgery: the big 6. SGLT2
2015 Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. ---
10  2015 Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors. IR
11  2014 Blood pressure-lowering effects of incretin-based diabetes therapies. DPP-4
12  2014 Cardiovascular effects of incretin therapy in diabetes care. DPP-4, T2DM
13  2014 Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes. OADs, T2DM
14  2013 Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. CV, DPP-4, T2DM
15  2009 Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. CNTF